Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1698924

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Greater Manchester: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when she last met with Greater Manchester NHS Board to discuss the statutory commissioning of NICE approved medicines.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20611
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20612 20613 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1698925

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Greater Manchester: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions NHS England have had with Greater Manchester NHS on their statutory responsibilities to commission NICE approved medicines.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20612
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20611 20613 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1698926

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Technology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what guidance her Department issues NHS trusts on establishing commissioning structures for Health Technology Assessments; and whether trusts have discretion to adopt different processes.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20613
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20611 20612 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1604145

	registered interest
	date	14/03/2023
	answering body	Department for Business and Trade
	answering dept id	214
	answering dept short name	Business and Trade
	answering dept sort name	Business and Trade
	hansard heading	Insolvency: Companies
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business and Trade, when the Government plans to publish its response to the consultation entitled Call for evidence: reviewing the personal insolvency landscape.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	165345
	answer	answer is ministerial correction date of answer 22/03/2023 answer text <p>The call for evidence on the review of the personal insolvency closed on 23 October 2022. The Government is currently analysing the significant number of responses and feedback received and will publish its response in due course.</p> answering member constituency Thirsk and Malton answering member printed Kevin Hollinrake question first answered 22/03/2023 17:06:18 answering member 4474 label Biography information for Kevin Hollinrake
	tabling member	4034 label Biography information for Yvonne Fovargue

1604147

	registered interest
	date	14/03/2023
	answering body	Department for Business and Trade
	answering dept id	214
	answering dept short name	Business and Trade
	answering dept sort name	Business and Trade
	hansard heading	Insolvency
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business and Trade, what information her Department holds on how many people have accessed a personal insolvency solution while the Insolvency Service has been conducting its Review of the personal insolvency framework.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	165346
	answer	answer is ministerial correction date of answer 22/03/2023 answer text <p>The number of people entering a formal personal insolvency solution since the commencement of the personal insolvency review at the beginning of July 2022 until 28 February 2023 was 74,124.</p><p> </p><p>The Insolvency Service publishes official statistics each month on the number of people entering a personal insolvency solution. The latest insolvency statistics can be accessed at <a href="https://www.gov.uk/government/statistics/monthly-insolvency-statistics-february-2023" target="_blank">https://www.gov.uk/government/statistics/monthly-insolvency-statistics-february-2023</a>.</p> answering member constituency Thirsk and Malton answering member printed Kevin Hollinrake question first answered 22/03/2023 17:07:13 answering member 4474 label Biography information for Kevin Hollinrake
	tabling member	4034 label Biography information for Yvonne Fovargue

1584996

	registered interest
	date	07/02/2023
	answering body	Department for Work and Pensions
	answering dept id	29
	answering dept short name	Work and Pensions
	answering dept sort name	Work and Pensions
	hansard heading	Unemployment: Insomnia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Work and Pensions, what assessment he has made of the potential impact of insomnia on the likelihood of people not being in employment or training.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	141450
	answer	answer is ministerial correction date of answer 15/02/2023 answer text <p>No assessment has been made. However, the Government has funded an extension of the Midlands’ Mental Health and Productivity Pilot, which is trialling interventions, including one with a focus on insomnia, to support and improve employee mental health and wellbeing, to support employees to remain in work. The final evaluation will be available by Spring 2024.</p><p> </p><p>In addition, a range of Government initiatives are supporting disabled people, and people with health conditions, including insomnia, to start, stay, and succeed in, work. These include:</p><p> </p><ul><li>Increasing Work Coach support in Jobcentres for people with health conditions receiving Universal Credit or Employment and Support Allowance;</li><li>Disability Employment Advisers in Jobcentres offering advice and expertise on how to help disabled people and people with health conditions into work;</li><li>The Work and Health Programme and Intensive Personalised Employment Support, providing tailored and personalised support for participants;</li><li>Access to Work grants towards the extra costs of working beyond standard reasonable adjustments;</li><li>Disability Confident, encouraging employers to think differently about disability and health, and to take positive action to address the issues employees face in the workplace;</li><li>The Information and Advice Service, providing better integrated and tailored guidance on supporting and managing health and disability in the workplace; and</li><li>Support in partnership between the DWP and the health system, including Employment Advice in NHS Talking Therapies, which combines psychological treatment and employment support for people with mental health conditions.</li></ul> answering member constituency Corby answering member printed Tom Pursglove question first answered 15/02/2023 12:06:58 answering member 4369 label Biography information for Tom Pursglove
	tabling member	4034 label Biography information for Yvonne Fovargue

1584997

	registered interest
	date	07/02/2023
	answering body	Department for Business and Trade
	answering dept id	214
	answering dept short name	Business and Trade
	answering dept sort name	Business and Trade
	hansard heading	Productivity: Insomnia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business and Trade, if she will make an assessment of the impact of insomnia on UK productivity.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	141451
	answer	answer is ministerial correction date of answer 15/02/2023 answer text <p>We have no plans to make an assessment of the impact on insomnia on UK productivity.</p> answering member constituency Wealden answering member printed Ms Nusrat Ghani question first answered 15/02/2023 15:31:43 answering member 4460 label Biography information for Ms Nusrat Ghani
	tabling member	4034 label Biography information for Yvonne Fovargue

1584998

	registered interest
	date	07/02/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Insomnia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to improve health outcomes for people with insomnia.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	141452
	answer	answer is ministerial correction date of answer 14/02/2023 answer text <p>Through ‘Advancing Our Health: Prevention in the 2020s’, the Government committed to review the evidence on sleep and health. That review has been undertaken, and the outcomes will be published in due course.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 14/02/2023 14:56:46 answering member 4679 label Biography information for Neil O'Brien
	tabling member	4034 label Biography information for Yvonne Fovargue

1584999

	registered interest
	date	07/02/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Insomnia: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the annual cost to the NHS of treating patients with insomnia.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	141453
	answer	answer is ministerial correction date of answer 14/02/2023 answer text <p>No assessment has been made by the Department or NHS England of the annual cost to the National Health Service for treating patients with insomnia.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 14/02/2023 14:52:01 answering member 4679 label Biography information for Neil O'Brien
	tabling member	4034 label Biography information for Yvonne Fovargue

1546153

	registered interest
	date	28/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Public Consultation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his planned timetable is for the publication of responses to the consultation entitled Advancing our health: prevention in the 2020s, published on 22 July 2019.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	97622
	answer	answer is ministerial correction date of answer 06/12/2022 answer text <p>We have no current plans to publish a summary of the responses to the consultation ‘Advancing our health: prevention in the 2020s’ and there are no plans to publish next steps.</p> answering member constituency Harborough answering member printed Neil O'Brien grouped question UIN 97624 question first answered 06/12/2022 15:53:43 answering member 4679 label Biography information for Neil O'Brien
	tabling member	4034 label Biography information for Yvonne Fovargue

1546156

	registered interest
	date	28/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Public Consultation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what his planned timetable is for the publication of next steps following the consultation entitled Advancing our health: prevention in the 2020s, published on 22 July 2019.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	97624
	answer	answer is ministerial correction date of answer 06/12/2022 answer text <p>We have no current plans to publish a summary of the responses to the consultation ‘Advancing our health: prevention in the 2020s’ and there are no plans to publish next steps.</p> answering member constituency Harborough answering member printed Neil O'Brien grouped question UIN 97622 question first answered 06/12/2022 15:53:43 answering member 4679 label Biography information for Neil O'Brien
	tabling member	4034 label Biography information for Yvonne Fovargue

1544606

	registered interest
	date	22/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rheumatoid Arthritis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many rheumatoid arthritis patients received a biologic in each of the last three years.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	93513
	answer	answer is ministerial correction date of answer 25/11/2022 answer text <p>This information is not collected in the format requested.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 93514 question first answered 25/11/2022 12:58:14 answering member 4527 label Biography information for Helen Whately
	tabling member	4034 label Biography information for Yvonne Fovargue

1544608

	registered interest
	date	22/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rheumatoid Arthritis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of rheumatoid arthritis patients received a biologic in the last 12 months.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	93514
	answer	answer is ministerial correction date of answer 25/11/2022 answer text <p>This information is not collected in the format requested.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 93513 question first answered 25/11/2022 12:58:14 answering member 4527 label Biography information for Helen Whately
	tabling member	4034 label Biography information for Yvonne Fovargue

1544610

	registered interest
	date	22/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of severe asthma patients have been prescribed a biologic in the last 12 months.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	93515
	answer	answer is ministerial correction date of answer 29/11/2022 answer text <p>The information on the proportion of severe asthma patients prescribed a biologic is not held in the format requested. However, 3,396 patients commenced a new biologic therapy for severe asthma in the last year. All those patients considered to benefit from a biologic treatment by a specialist severe asthma team will have received the treatment.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 93516 question first answered 29/11/2022 15:37:05 answering member 4527 label Biography information for Helen Whately
	tabling member	4034 label Biography information for Yvonne Fovargue

1544613

	registered interest
	date	22/11/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many severe asthma patients were refused biologic treatment in the last 12 months.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	93516
	answer	answer is ministerial correction date of answer 29/11/2022 answer text <p>The information on the proportion of severe asthma patients prescribed a biologic is not held in the format requested. However, 3,396 patients commenced a new biologic therapy for severe asthma in the last year. All those patients considered to benefit from a biologic treatment by a specialist severe asthma team will have received the treatment.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 93515 question first answered 29/11/2022 15:37:05 answering member 4527 label Biography information for Helen Whately
	tabling member	4034 label Biography information for Yvonne Fovargue

1491401

	registered interest
	date	21/07/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lung Diseases: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to amend the respiratory outcomes section in the update of the NHS Long Term Plan.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41993
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>The Department and NHS England are currently reviewing delivery of the commitments made in the NHS Long Term Plan, including those relating to respiratory outcomes. The update to the NHS Long Term Plan will be published later this year.</p><p>There are no current plans to include metrics measuring uptake of biologics in the NHS Long Term Plan update. However, pathways to biologic therapy are being streamlined, including through the Accelerated Access Collaborative’s work to improve the identification of patients in primary and secondary care settings for referrals to assess suitability to receive biologic treatment.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 41994 question first answered 05/09/2022 11:27:51 answering member 4680 label Biography information for Gillian Keegan
	tabling member	4034 label Biography information for Yvonne Fovargue

1491402

	registered interest
	date	21/07/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asthma: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, If he will include metrics on the uptake of biologics for severe asthma in the update to the NHS Long Term Plan.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41994
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>The Department and NHS England are currently reviewing delivery of the commitments made in the NHS Long Term Plan, including those relating to respiratory outcomes. The update to the NHS Long Term Plan will be published later this year.</p><p>There are no current plans to include metrics measuring uptake of biologics in the NHS Long Term Plan update. However, pathways to biologic therapy are being streamlined, including through the Accelerated Access Collaborative’s work to improve the identification of patients in primary and secondary care settings for referrals to assess suitability to receive biologic treatment.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 41993 question first answered 05/09/2022 11:27:51 answering member 4680 label Biography information for Gillian Keegan
	tabling member	4034 label Biography information for Yvonne Fovargue

1491423

	registered interest
	date	21/07/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Obstructive Pulmonary Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has plans to include incentives within the Quality and Outcomes Framework or Investment and Impact Fund to help ensure that chronic obstructive pulmonary disease (COPD) patients receive a proactive review of their care after a prescription of oral corticosteroid for a COPD exacerbation.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41995
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>We have no specific plans to do so. However, the Quality and Outcomes Framework and the Investment and Impact Fund are reviewed to ensure alignment with the latest clinical guidance and best practice.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 05/09/2022 10:38:51 answering member 3992 label Biography information for James Morris
	tabling member	4034 label Biography information for Yvonne Fovargue

1491425

	registered interest
	date	21/07/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Obstructive Pulmonary Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of patients who have received all components of the discharge bundle included in the Best Practice Tariff for chronic obstructive pulmonary disease in the last 12 months.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41996
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>No specific estimate has been made. Compliance with the Best Practice Tariff criteria is measured by the National COPD Audit Programme’s secondary care audit.</p><p> </p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 05/09/2022 10:40:38 answering member 3992 label Biography information for James Morris
	tabling member	4034 label Biography information for Yvonne Fovargue

1491427

	registered interest
	date	21/07/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Obstructive Pulmonary Disease: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has plans to include measures to promote an increase in treatment reviews of chronic obstructive pulmonary disease patients who are risk of exacerbation within CORE20+5.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41997
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>There are no plans to do so. However, Core20PLUS5 supports increasing the uptake of COVID-19, flu and pneumonia vaccines to reduce infective exacerbations and potential emergency hospital admissions.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 05/09/2022 11:13:19 answering member 3992 label Biography information for James Morris
	tabling member	4034 label Biography information for Yvonne Fovargue

1491429

	registered interest
	date	21/07/2022
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Fluorinated Gases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Environment, Food and Rural Affairs, whether his Department has conducted modelling on the impact of the potential removal of medical exemption to the F gas phase down schedule on the cost of medicines.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41998
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>Defra is reviewing the F-gas Regulation, which includes an exemption from the hydrofluorocarbon phasedown for metered dose inhalers (MDIs). The review will consider the implementation of the current F-gas Regulation and options for future policy development. The implications of removing the exemption for MDIs, including the potential impact of this on cost and supply, will be included in the analysis.</p><p> </p><p>NHS England is in the process of reducing the use of MDIs containing high global warming potential propellants and has produced cost estimates for the switch from MDIs to currently readily available alternatives. These cost estimates will be incorporated in Defra’s work.</p><p> </p><p>Defra is working on this review jointly with the Scottish and Welsh Governments and we plan to consult on proposed future policies next year.</p> answering member constituency St Austell and Newquay answering member printed Steve Double question first answered 05/09/2022 07:09:16 answering member 4452 label Biography information for Steve Double
	tabling member	4034 label Biography information for Yvonne Fovargue

1491432

	registered interest
	date	21/07/2022
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Fluorinated Gases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Environment, Food and Rural Affairs, if he will hold discussions with the Secretary of State for Health and Social Care on a timescale for the phasedown of the use of fluorinated gases in asthma inhalers.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	41999
	answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>Defra has a legal duty to undertake a comprehensive review of the F-gas Regulation. As part of this work, Defra will identify additional action that can be taken with regard to F-gases and their contribution to net zero. At COP26, Defra committed to an accelerated hydrofluorocarbon (HFC) phasedown. Defra intends to publish an assessment report by the end of 2022 as the first stage of the review. It will focus mainly on analysing the effects of the current Regulation, together with the current state of play in relevant industry sectors and international commitments. The second stage of the review will involve a public consultation on proposals for any legislative changes.</p><p>The F-gas Regulation currently includes an exemption from the HFC phasedown for metered dose inhalers (MDIs). The continuation or removal of the exemption for MDIs will be considered as part of the policy development and analysis into future options, as well as implications of the HFC phasedown on MDIs. To support this work there is ongoing engagement between Defra, the NHS and the Department of Health and Social Care.</p> answering member constituency St Austell and Newquay answering member printed Steve Double question first answered 05/09/2022 07:05:41 answering member 4452 label Biography information for Steve Double
	tabling member	4034 label Biography information for Yvonne Fovargue

1487016

	registered interest
	date	06/07/2022
	answering body	Department for Work and Pensions
	answering dept id	29
	answering dept short name	Work and Pensions
	answering dept sort name	Work and Pensions
	hansard heading	Silica: Health and Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Work and Pensions, what steps she has taken to help reduce exposure to respirable crystalline silica in the workplace.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	31816
	answer	answer is ministerial correction date of answer 12/07/2022 answer text <p>The Health and Safety Executive (HSE) has a well-established regulatory framework in place to protect workers from the health risks associated with exposure to hazardous substances at work.</p><p> </p><p>Under the <a href="https://www.legislation.gov.uk/uksi/2002/2677/introduction/made" target="_blank">Control of Substances Hazardous to Health Regulations 2002 (COSHH)</a> employers have a duty to prevent or adequately control worker exposure to hazardous substances such as Respirable Crystalline Silica (RCS). COSHH sets out the hierarchy of control that must be implemented and, if managed appropriately, should result in achieving a level below the Work Exposure Limit (WEL) as detailed in HSE Guidance ‘<a href="https://www.hse.gov.uk/pubns/books/eh40.htm" target="_blank">EH40/2005, Workplace exposure limits</a>’.</p><p><br> HSE also delivers communications campaigns to support its regulatory activity. These campaigns inform duty holders and workers of the hazards faced and how these should be controlled and monitored. HSE’s dust campaign which ran in late 2021, included silica exposure, and involved social media and press activity to support awareness of the risks and how to control them.</p> answering member constituency Norwich North answering member printed Chloe Smith question first answered 12/07/2022 12:08:54 answering member 1609 label Biography information for Chloe Smith
	tabling member	4034 label Biography information for Yvonne Fovargue

1487017

	registered interest
	date	06/07/2022
	answering body	Department for Work and Pensions
	answering dept id	29
	answering dept short name	Work and Pensions
	answering dept sort name	Work and Pensions
	hansard heading	Silicosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Work and Pensions, whether she plans to make silicosis a notifiable disease under the Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 2013.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	31817
	answer	answer is ministerial correction date of answer 12/07/2022 answer text <p>The Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 2013 (RIDDOR) are made under the Health and Safety at Work etc. Act 1974 and apply to all sectors and workplaces in Great Britain.</p><p> </p><p>The 2013 regulations clarified and simplified the list of reportable ill-health conditions (occupational diseases), as a result of a recommendation made by Professor Löfstedt in his report “<a href="https://www.gov.uk/government/publications/reclaiming-health-and-safety-for-all-lofstedt-report" target="_blank">Reclaiming health and safety for all: An independent review of health and safety legislation</a>,” published in 2011.</p><p> </p><p>The Health and Safety Executive (HSE) keeps the regulations, including specified injuries and reportable diseases, under review. The list of current reportable occupational diseases, including silicosis, will be considered as part of the next formal post-implementation review of RIDDOR, which is due to report in October 2023. HSE will engage with a range of stakeholders as part of the review process.</p> answering member constituency Norwich North answering member printed Chloe Smith question first answered 12/07/2022 12:05:42 answering member 1609 label Biography information for Chloe Smith
	tabling member	4034 label Biography information for Yvonne Fovargue

1487018

	registered interest
	date	06/07/2022
	answering body	Department for Work and Pensions
	answering dept id	29
	answering dept short name	Work and Pensions
	answering dept sort name	Work and Pensions
	hansard heading	Silica: Health and Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Work and Pensions, if she will reduce the Workplace Exposure Limit in the UK for silica related work to 0.05 mg/m3 in line with other countries.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	31818
	answer	answer is ministerial correction date of answer 12/07/2022 answer text <p>The Health and Safety Executive (HSE) does not currently intend to review the Workplace Exposure Limit (WEL) of Respirable Crystalline Silica (RCS) in Great Britain. HSE contributed to the more recent European Union (EU) assessment of the limit in January 2019, where the EU reclassified RCS as a carcinogen and implemented the same occupational exposure limit as already existed in GB.</p><p> </p><p>HSE will continue to monitor international developments in this area and the evidence base to consider the range of interventions that might be suitable, including any change to the exposure limit in GB.</p> answering member constituency Norwich North answering member printed Chloe Smith question first answered 12/07/2022 11:57:39 answering member 1609 label Biography information for Chloe Smith
	tabling member	4034 label Biography information for Yvonne Fovargue